Loading provider…
Loading provider…
Diagnostic Radiology Physician in Philadelphia, PA
NPI: 1083872956Primary Practice Location
HOSPITAL OF UNIV OF PENNSYLVANIA
3400 Spruce St, Philadelphia, PA
Primary Employer
University of Penn-Medical Group
pathology.med.upenn.edu
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
NJ State Medical License
2014 - 2027
PA State Medical License
2013 - 2026
NY State Medical License
2008 - 2013

American Board of Nuclear Medicine
Nuclear Medicine

American Board of Radiology
Diagnostic Radiology
Vagelos College of Physicians and Surgeons
vagelos.columbia.edu
Medical School
Until 2007
New York Presbyterian Hospital (Columbia Campus)
Fellowship • Nuclear Radiology
2012 - 2013
Residency • Radiology-Diagnostic
2008 - 2012
Icahn School of Medicine at Mount Sinai/Morningside/West
Internship • Internal Medicine
2007 - 2008
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 78815Nuclear medicine study with CT imaging skull base to mid-thigh | 380 | 393 |
| 2 | 78816Nuclear medicine study with CT imaging whole body | 65 | 65 |
| 3 | A9552Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 59 | 61 |
| 4 | 78306Bone and/or joint imaging, whole body | 44 | 44 |
| 5 | 78830Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, with concurrently acquired ct transmission scan, 1 day of imaging | 29 | 29 |
Authors: David Mankoff
Journal: JAMA Oncol
In vivo visualization of PARP inhibitor pharmacodynamics.
Authors: Daniel Pryma, Elizabeth Mcdonald, Amy Clark
Publication Date: 2020-12-03
Lead Sponsor: ImaginAb, Inc.
Intervention / Treatment: DRUG: ⁸⁹Zr-Df-IAB22M2C